Candriam S.C.A. Grows Stock Holdings in Exelixis, Inc. $EXEL

Candriam S.C.A. increased its stake in Exelixis, Inc. (NASDAQ:EXEL) by 18.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 696,104 shares of the biotechnology company’s stock after purchasing an additional 108,367 shares during the quarter. Candriam S.C.A. owned 0.26% of Exelixis worth $28,749,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. AQR Capital Management LLC lifted its holdings in shares of Exelixis by 10.3% during the 2nd quarter. AQR Capital Management LLC now owns 7,606,079 shares of the biotechnology company’s stock valued at $335,238,000 after buying an additional 712,190 shares during the period. Geode Capital Management LLC increased its position in Exelixis by 0.4% during the second quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock valued at $328,196,000 after acquiring an additional 28,289 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Exelixis by 42.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock valued at $231,951,000 after acquiring an additional 1,580,567 shares during the period. Qube Research & Technologies Ltd boosted its position in Exelixis by 120.5% in the second quarter. Qube Research & Technologies Ltd now owns 3,047,222 shares of the biotechnology company’s stock worth $134,306,000 after purchasing an additional 1,665,110 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Exelixis during the 2nd quarter valued at about $122,099,000. Institutional investors own 85.27% of the company’s stock.

Exelixis Price Performance

EXEL stock opened at $43.95 on Tuesday. Exelixis, Inc. has a 1-year low of $32.38 and a 1-year high of $49.62. The business has a 50 day simple moving average of $43.70 and a two-hundred day simple moving average of $40.94. The company has a market capitalization of $11.78 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 0.74 and a beta of 0.42.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director Stelios Papadopoulos sold 100,000 shares of Exelixis stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total value of $4,355,000.00. Following the sale, the director directly owned 1,189,228 shares in the company, valued at approximately $51,790,879.40. The trade was a 7.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Patrick J. Haley sold 34,187 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $41.88, for a total transaction of $1,431,751.56. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 172,230 shares of company stock valued at $7,401,923 over the last ninety days. 2.85% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Guggenheim cut shares of Exelixis from a “buy” rating to a “neutral” rating in a research note on Monday, November 3rd. Zacks Research raised shares of Exelixis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Citigroup downgraded shares of Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Leerink Partners raised shares of Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a research report on Tuesday, October 21st. Finally, Oppenheimer restated a “market perform” rating and issued a $36.00 price objective on shares of Exelixis in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $46.16.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.